Eli Lilly and Company (LLY) Stake Boosted by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 171,587 shares of the company’s stock after acquiring an additional 1,895 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Eli Lilly and were worth $14,122,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of LLY. Acrospire Investment Management LLC increased its position in shares of Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. San Francisco Sentry Investment Group CA purchased a new position in shares of Eli Lilly and during the second quarter valued at about $129,000. Point72 Asia Hong Kong Ltd increased its position in shares of Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the period. Shine Investment Advisory Services Inc. purchased a new position in shares of Eli Lilly and during the second quarter valued at about $148,000. Finally, Cornerstone Advisors Inc. increased its position in shares of Eli Lilly and by 18.4% during the second quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock valued at $166,000 after buying an additional 313 shares during the period. 76.61% of the stock is owned by hedge funds and other institutional investors.
LLY has been the topic of several research analyst reports. BMO Capital Markets reiterated a “sell” rating and set a $73.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. BidaskClub cut shares of Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $89.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Finally, Leerink Swann reiterated a “hold” rating on shares of Eli Lilly and in a research report on Thursday, August 31st. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $90.25.
Shares of Eli Lilly and Company (LLY) opened at $84.03 on Friday. The firm has a market cap of $92,139.64, a PE ratio of 20.46, a price-to-earnings-growth ratio of 1.85 and a beta of 0.34. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a fifty-two week low of $65.66 and a fifty-two week high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.88 earnings per share. equities analysts expect that Eli Lilly and Company will post 4.21 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the company’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the sale, the insider now owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The disclosure for this sale can be found here. In the last 90 days, insiders sold 772,003 shares of company stock worth $64,837,441. Corporate insiders own 0.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/eli-lilly-and-company-lly-stake-boosted-by-raymond-james-financial-services-advisors-inc/1725895.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.